Rocuronium Bromide Injection Shortage: Current Availability and Manufacturer Updates
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Rocuronium Bromide Injection, a medication used in anesthesia, is currently in shortage with some manufacturers reporting limited availability while others remain in supply.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, RocuroniumBromide) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Rocuronium Bromide Injection (brand names: ROCURONIUM BROMIDE, ROCURONIUM) is currently listed as being in shortage. This medication belongs to the therapeutic category of Anesthesia. The shortage affects various presentations of the injection, including 10 mg/1 mL, 50 mg/5 mL, and 100 mg/10 mL dosages.
Which Manufacturers Are Affected
Several manufacturers are involved in the production of Rocuronium Bromide Injection, with varying levels of availability:
- Mylan Institutional, a Viatris Company:
- 10 mg/1 mL (NDC 67457-228-05): Available
- 10 mg/1 mL (NDC 67457-228-10): Unavailable (Re-supply expected March 2026)
- Contact: 800-796-9526
- Fresenius Kabi USA, LLC:
- 10 mg/1 mL (NDC 65219-444-10): Available (Check wholesalers for inventory)
- 10 mg/1 mL (NDC 63323-426-05): Unavailable (Next release expected March 2026; check wholesalers for inventory)
- Contact: 888-386-1300
- Sagent Pharmaceuticals:
- 10 mg/1 mL (NDC 25021-687-05): Available
- Contact: 866-625-1618
- Eugia US LLC:
- 100 mg/10 mL (NDC 55150-226-10): Available (Check wholesalers for inventory)
- 50 mg/5 mL (NDC 55150-225-05): Available (Check wholesalers for inventory)
- Contact: 888-238-7880
- Baxter Healthcare:
- 50 mg/5 mL (NDC 43066-007-10): Available
- 100 mg/10 mL (NDC 43066-013-10): Available
- Contact: 888-229-0001
- Sandoz Inc.:
- 10 mg/1 mL (NDC 0781-3220-95): Available
- 10 mg/1 mL (NDC 0781-3220-92): Available
- Contact: 800-525-8747
Why There's a Shortage
No specific reason for the shortage was provided in the official documentation. Some manufacturers have indicated that re-supply or next releases for specific presentations are expected in March 2026.
What Patients Should Do
Rocuronium Bromide is typically administered by healthcare professionals in a clinical or hospital setting. If you are a patient with concerns about this medication's availability for an upcoming procedure, please:
- Consult with your healthcare provider or anesthesiologist regarding your treatment plan.
- Ask your pharmacist or hospital supply coordinator about current inventory levels.
- Healthcare facilities may contact the manufacturers directly using the phone numbers provided above for the most current shipping information.
Patients should always consult their healthcare provider regarding any changes to their medical care.
Source
Information provided by the FDA Drug Shortage Database.
Initial Posting Date: 02/15/2023
Last Updated: 02/05/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category